Alpha-carboline compound or pharmaceutical composition thereof as well as preparation method and application of alpha-carboline compound

The invention discloses an alpha-carboline compound or a pharmaceutical composition thereof as well as a preparation method and application of the alpha-carboline compound, and the alpha-carboline compound is N1-substituted quaternary ammonium salt, can effectively inhibit the activity of cholinesterase AChE and BuChE, has anti-neuritis activity, and can be used for preparing anti-neuritis drugs. The compound can be developed into drugs for preventing and/or treating neurodegenerative diseases (such as Alzheimer's disease), neuritis diseases and other related diseases..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 28. März Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

DAI JIANGKUN [VerfasserIn]
CAO YIDAN [VerfasserIn]
LIU JINYI [VerfasserIn]
ZHANG JIAOYUE [VerfasserIn]
GAO JIXIANG [VerfasserIn]
DAN WENJIA [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07D: Heterocyclic compounds (macromolecular compounds c0 (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-03-28, Last update posted on www.tib.eu: 2023-06-27, Last updated: 2023-06-30

Patentnummer:

CN115850270

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA017246113